Unlike in fee-for-service, we have an amazing opportunity to begin to understand and build in factors that will keep patients healthy and give them the best outcomes possible, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.
Unlike in fee-for-service, we have an amazing opportunity to begin to understand and build in factors that will keep patients healthy and give them the best outcomes possible, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.
Transcript:
Are payers and providers getting a better handle on concepts like social determinants of health and more holistic care for patients?
Absolutely, yes. I think the value-based models create a really profound opportunity for us to begin to think about healthcare in managed care in a completely new way and in a way that brings in social determinants of health and also brings in non-traditionally covered services. For example, in fee-for-service, generally an Uber, a car service won't be covered to have a member transferred from their home to a doctor to get to an appointment. It's an incremental cost of care. It's not a covered benefit. The answer is generally no. As we move into value-based care, and we focus on outcomes, now we think about what are those services or social determinants, what things actually have an impact on the patient's outcome. Certainly as we think about getting a patient to the doctor that has a very significant impact on their outcome. Now, using this very simple example, Uber or Lyft, or some other car service, for example, could very well become part of the healthcare continuum, part of these value-based models. In the same way, we've started now to see food programs and housing programs being incorporated into models and being paid for by health plans. Again, not traditionally covered services. But now there's willingness to really bring them in and pay for them because there's understanding of the importance of having clean and safe housing on one's health or transporting somebody to the doctor or making sure they have nutritious food. That gets me really excited. I think, unlike in fee-for-service, we really have an amazing opportunity with these models to begin to understand and build in those things that will really keep patients healthy and if they're not already healthy, give them the best experience and best outcomes possible.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
2 Commerce Drive
Cranbury, NJ 08512